Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 139
- 主要终点
- Relapse of hyperthyroidism
研究概览
简要总结
ATD therapy for Graves' disease is one of the commonly used options for therapy of the hyperthyroidism. The investigators study how to optimally keep patients in remission.
详细描述
A detailed description of patients entering the initial observational phase of the study (RISG1) has been published:
Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Graves hyperthyroidism in remission after ATD
排除标准
- •Age < 18, severe concomitant disease
结局指标
主要结局
Relapse of hyperthyroidism
时间窗: 2 years
次要结局
- Reoccurrence of TSH-receptor autoimmunity(2 years)
研究者
Jesper Scott Karmisholt
MD
Aalborg University Hospital
